Publication Date:
1989-01-06
Description:
Plasminogen activator therapy for acute myocardial infarction has become standard medical practice. Bleeding complications, however, limit the utility of the currently available agents. This article reviews how the tools of molecular biology and protein engineering are being used to develop safer and more effective plasminogen activators.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Haber, E -- Quertermous, T -- Matsueda, G R -- Runge, M S -- HL-19259/HL/NHLBI NIH HHS/ -- HL-28015/HL/NHLBI NIH HHS/ -- New York, N.Y. -- Science. 1989 Jan 6;243(4887):51-6.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Cardiac Unit, Massachusetts General Hospital, Boston 02114.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/2492113" target="_blank"〉PubMed〈/a〉
Keywords:
Humans
;
Myocardial Infarction/*drug therapy
;
Plasminogen Activators/*therapeutic use
;
Protein Conformation
;
Recombinant Proteins/therapeutic use
;
Streptokinase/therapeutic use
;
Tissue Plasminogen Activator/therapeutic use
;
Urokinase-Type Plasminogen Activator/therapeutic use
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink